)The top 100 stock
market authors
selected for publication
market authors
selected for publication
Ax
»
Comments
» Single Comment
| 
-
The Seeking Alpha 100
See all
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largestSee all
increase in followers
in the last 7 days
Fastest Climbers » -
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most activeSee all
Instabloggers.
Top Instabloggers » -
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
-
I agree completely with the post above from pharma... although I am no expert on medical studies. I think the reporting about the new drug Erbitux was just spin. The market and the media wanted to see Genentech drug to look superior.
Jun 04 09:49 am
|Rating:
0
0
All Comments by Ax »Bristol-Myers, ImClone, Genentech Release Promising Data at ASCO [View article]
The reports focused only on the 40% that the Erbitux drug doesn't apply too... and no one mentioned the other 60%. When you get a drug that shows superior results on a specific segment of people, there is no doubt that the drug will be prescribed to them.
Also we must not forget that when Mike Huckman asked at the ASCO the doctors if they would prescribe Erbitux to their patients the vast majority said yes. And the one that wasn't sure was from Canada.